Esperion Therapeutics ESPR Royalty sale liability
Royalty sale liability at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept espr:RoyaltySaleLiabilityNonCurrent.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's royalty sale liability.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's royalty sale liability?
- Esperion Therapeutics (ESPR) reported royalty sale liability of $210.43M in Q1 2026.
- How has Esperion Therapeutics's royalty sale liability changed year-over-year?
- Esperion Therapeutics's royalty sale liability decreased by 11.9% year-over-year, from $238.98M to $210.43M.
- What does royalty sale liability mean?
- This represents the long-term portion of obligations arising from the sale of future royalty rights to third-party investors. It indicates the extent to which the company has leveraged its intellectual property to secure long-term funding. This metric is essential for assessing the long-term impact of financing arrangements on future profitability.